Breaking News, Trials & Filings

TGT Starts CLL, MCL Trial

Will test combo of anti-CD20 MAb with Janssen/Pharmacyclics' Imbruvica

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

TG Therapeutics has begun a multi-center Phase II trial to evaluate the safety and efficacy of the combination of TG-1101 (ublituximab) and Imbruvica (ibrutinib) for patients with Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL). This will be the first clinical trial evaluating the combination of TG-1101, the company’s novel glycoengineered anti-CD20 monoclonal antibody, and ibrutinib, the oral Bruton Tyrosine Kinase (BTK) inhibitor which was recently granted approval by t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters